TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Procedural Device Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collateral Flow index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Hba1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of gene mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Negative Symptoms of Schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinical cure, clinical failure, or indeterminate clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal protective effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Ability for two-point discrimination of the injured finger
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Bone Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal thickness (MT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Device success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Child Problem Behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Shoulder disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Longitudinal variation of the relative regional cerebral blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AGIS scores of HVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with no incidence of major surgical or device related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in palmer arsenical keratosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Osimertinib AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2 at Anaerobic Threshold (VO2@AT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-translational modifications of Cu/Zn superoxide dismutase 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proximal force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Distal force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Breast Cancer Knowledge Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Impact of Events Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PrEP Adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative 6-minute walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Occupational Performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recommended Phase II dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average hours per night using HHHFNC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average hours per night using CPAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal visualisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of type 2 diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resolution of obesity co-morbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic performance of axillary MRL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Metabolic response to acute ingestion of fat and glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in MADRS Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of intrusive memories
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (R2PD) of Entinostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Adverse Events for Entinostat
Endpoint domain: Adverse events/effects
Primary endpoint: Peak Plasma Concentration of Entinostat: C-Max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability (adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of Intranasal Administration of modified Temozolomide
Endpoint domain: Adverse events/effects
Primary endpoint: Intraocular VEGF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular PLGF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of B Lymphocytes in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of B Lymphocytes in iLN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of CD56+ NK Cells in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Abstinent From Tobacco at Week 12 (7 Day Point Prevalence)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Prolonged Abstinence From Tobacco at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Abstinent From Tobacco at Week 26 (7 Day Point Prevalence)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Prolonged Abstinence From Tobacco at Week 26
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Abstinent From Tobacco at Week 32 (7 Day Point Prevalence)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 2 year Recurrence-Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Duration of Recurrence-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of patient care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Number of participants with reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Sputum Density of BCC in CFUs/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of nonfatal myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of nonfatal stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Number of alerts initiated
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patent Indwell Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: severe COVID-19 outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Stability of Nail Polish
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of cumulative drug excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Plasma Concentration [Cmax]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to plasma peak concentration [Tmax]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of true/false positive and true/false negative detections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of patients needing rehydration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Histopathological Regression of Cervical Lesions to CIN1 or Less
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: SF-36 Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Center for Epidemiological Depression Scale-Revised
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: occurrence of an adverse drug reaction (ADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Pathological complete response in the breast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PrEP Uptake at Week 1
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical status at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial natriuretic peptide (ANP) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Insulin Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Theory of mind performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy in theory of mind performance after cyberball
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction time in theory of mind performance after cyberball
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of DVT
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of Symptomatic Nonlethal Thromboembolia of the Pulmonary Artery (PATE)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Venous Thromboembolism Death
Endpoint domain: Mortality/survival
Primary endpoint: Improvement from severe type to common type
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on Performance-Based Measures of Functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Increase of ER Protein Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of Oculomotor disorders (OMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose of Sorafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline taurine plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Subject Time Spent on Cardiopulmonary Cross Clamp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average Amount of Time Subject Spent on Cardiopulmonary Bypass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Social Skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Grade Point Average
Endpoint domain: Life impact
Endpoint subdomain: Academic performance
Primary endpoint: Safety Evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: Device Functionality Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Death
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success Rate of Pupal Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migration as measured by RSA maximal total point motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Receiving Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fraction of Inspired Oxygen (FiO2)/Partial Arterial Oxygen Pressure (PO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Acute Physiology and Chronic Health Evaluation (APACHE) II Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Major adverse cardiovascular events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the plasma semaglutide concentration curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax, the maximum plasma semaglutide concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurodevelopment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Disability levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fear and phobia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar spine density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity to lactic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Overall Survival (OS)
Endpoint domain: Mortality/survival
Primary endpoint: Change in dermal safety (Draize) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of menses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Completion of puberty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Fertility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Detection of β Thalassemia Carriers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Task Persistence - Mirror Tracing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Task Persistence - Sustained Divided Attention Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Task Persistence - Breath-holding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follicular survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of post cesarean wound related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Self-Reported Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Copenhagen Achilles Length Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Retention Alpha for restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reconstruction failure
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Nasolabial Folds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of abnormal endometrial patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Post-void residual volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety of XG-102
Endpoint domain: Adverse events/effects
Primary endpoint: Quantity of CTCs isolated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy Root Mean Square (ARMS) of SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of recurrence of herpes simplex virus
Endpoint domain: Adverse events/effects
Primary endpoint: Metacarpophalangeal joint contracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 2 hours plasma glucose value (mmol/l)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: light adapted electroretinogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nonexercise activity thermogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to delivery
Endpoint domain: Mortality/survival
Primary endpoint: Muscle Tone as Measured by the Modified Ashworth Scale (MAS) in the Elbow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle Tone as Measured by the Modified Ashworth Scale (MAS) in the Wrist
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle Tone as Measured by the Modified Ashworth Scale (MAS) in the Fingers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle Tone as Measured by the Modified Ashworth Scale (MAS) in the Thumb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Sleep Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary Vascular Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absolute Bioavailability (F[abs]) of JNJ-42756493
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Bioavailability (F[rel]) of JNJ-42756493
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mental health symptom levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Impaired functioning levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety and tolerability of combination therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with plasma concentration of sunitinib greater than 100 ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood glucose level Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cholesterol level Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Investigator Global Assessment (IGA) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: %Change in FLT Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase 2 Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of newborns needing endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time taken to insert needle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin A, Glycosylated (Hba1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical relevant bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Power Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Simplified Disease Activity Index (SDAI) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left atrial performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ER visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: SMBG values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathological measurement of tumour tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diffusion/flow of tissue water (ADC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in score on the Hamilton Anxiety Rating Scale (HAM-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients admitted to a medical / surgical service within 7 days of psychiatry referral
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of days after psychiatric referral that patient is admitted to medical / surgical service
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MRI T2-map values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of the Influenza virus vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes